Zacks Investment Research on MSN11h
VKTX Finishes Enrolment in Mid-Stage Study on Oral Weight-Loss Drug
Viking Therapeutics VKTX announced that it has completed enrolling study participants in the phase II VENTURE-Oral Dosing ...
BioPharma Dive3d
Novo adds to obesity drug pipeline via $200M deal with China-based biotech
The licensing pact adds a second so-called "triple agonist" to the Danish drugmaker's portfolio as competition with Lilly and other contenders heats up.